HK1072600A1 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors - Google Patents

Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Info

Publication number
HK1072600A1
HK1072600A1 HK05105260A HK05105260A HK1072600A1 HK 1072600 A1 HK1072600 A1 HK 1072600A1 HK 05105260 A HK05105260 A HK 05105260A HK 05105260 A HK05105260 A HK 05105260A HK 1072600 A1 HK1072600 A1 HK 1072600A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
serotonin reuptake
reuptake inhibitors
piperazine derivatives
piperazine
Prior art date
Application number
HK05105260A
Other languages
English (en)
Inventor
Thomas Ruhland
Garrick Paul Smith
Benny Bang-Andersen
Ask Puschl
Ejner Knud Moltzen
Kim Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1072600(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK1072600A1 publication Critical patent/HK1072600A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK05105260A 2001-10-04 2005-06-23 Phenyl-piperazine derivatives as serotonin reuptake inhibitors HK1072600A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (1)

Publication Number Publication Date
HK1072600A1 true HK1072600A1 (en) 2005-09-02

Family

ID=8160750

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05105260A HK1072600A1 (en) 2001-10-04 2005-06-23 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Country Status (39)

Country Link
US (10) US7144884B2 (lt)
EP (2) EP1749818B1 (lt)
JP (3) JP3896116B2 (lt)
KR (3) KR100783346B1 (lt)
CN (1) CN1319958C (lt)
AR (2) AR036659A1 (lt)
AT (2) ATE441631T1 (lt)
AU (2) AU2002333220C1 (lt)
BE (1) BE2014C036I2 (lt)
BR (3) BR122012023120B8 (lt)
CA (1) CA2462110C (lt)
CO (1) CO5580746A2 (lt)
CY (3) CY1107924T1 (lt)
DE (2) DE60225162T3 (lt)
DK (2) DK1749818T3 (lt)
EA (2) EA007537B3 (lt)
EG (1) EG25095A (lt)
ES (2) ES2298425T7 (lt)
FR (1) FR14C0033I2 (lt)
HK (1) HK1072600A1 (lt)
HR (1) HRP20040220A2 (lt)
HU (3) HU228956B1 (lt)
IL (1) IL160655A0 (lt)
IS (2) IS2578B (lt)
LT (1) LTC1436271I2 (lt)
LU (1) LU92397I2 (lt)
ME (1) ME00039B (lt)
MX (1) MXPA04002959A (lt)
MY (1) MY140950A (lt)
NL (1) NL300652I2 (lt)
NO (3) NO326443B1 (lt)
NZ (1) NZ531556A (lt)
PL (2) PL210551B1 (lt)
PT (2) PT1749818E (lt)
RS (2) RS52326B (lt)
SI (1) SI1436271T1 (lt)
UA (2) UA81749C2 (lt)
WO (1) WO2003029232A1 (lt)
ZA (1) ZA200401583B (lt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
AU2004226838B8 (en) * 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
ZA200507181B (en) * 2003-04-04 2007-03-28 Lundbeck & Co As 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
PT1635828E (pt) * 2003-04-04 2008-07-01 Lundbeck & Co As H Derivados de 4-(2-feniloxifenil) piperidina ou de 1,2,3,6-tetrahidropiridina como inibidores da recaptação da serotonina
EA009417B1 (ru) * 2003-04-04 2007-12-28 Х. Лундбекк А/С Производные 4-(2-фенилоксифенил)пиперидина или -1,2,3,6-тетрагидропиридина в качестве ингибиторов обратного захвата серотонина
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
MXPA06007172A (es) 2003-12-23 2006-08-23 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-bencilamina como ssri.
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
EP1851207B1 (en) * 2005-02-10 2009-07-01 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
ZA200809917B (en) * 2006-06-16 2010-08-25 Lundbeck & Co As H Crystalline forms of 4- [2-(4-Methylphenylsulfanyl) - Phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
EP2044043B2 (en) * 2006-06-16 2021-03-03 H. Lundbeck A/S 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
AR061480A1 (es) * 2006-06-16 2008-08-27 Lundbeck & Co As H 4-[2-(4-metilfenilsulfanil)-fenil]piperidina como inhibidor combinado de la recaptacion de serotonina y norepinefrina.
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
WO2008151632A1 (en) 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
RU2503662C2 (ru) 2008-11-14 2014-01-10 Тереванс, Инк. Кристаллическая форма 4-[2-(2-фторфеноксиметил)фенил]пиперидинового соединения
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
MX2011011119A (es) * 2009-04-24 2011-11-04 Lundbeck & Co As H Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina.
UA105057C2 (uk) * 2009-08-24 2014-04-10 Х. Луннбек А/С Композиція 1-[2-(2,4-диметилфенілсульфаніл)феніл]-піперазину
IN2012DN03846A (lt) * 2009-10-30 2015-08-28 Janssen Pharmaceutica Nv
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
GEP20166487B (en) 2010-04-30 2016-06-10 Takeda Pharmaceutical Enteric tablet
MA34261B1 (fr) * 2010-04-30 2013-05-02 Takeda Pharmaceutcal Company Ltd Comprime a delitage intestinal
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
PE20141113A1 (es) 2011-06-20 2014-09-25 Lundbeck & Co As H 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
IN2014DN04226A (lt) 2011-11-14 2015-05-22 Gen Hospital Corp
CN104011034B (zh) * 2012-01-03 2016-08-17 H.隆德贝克有限公司 用于生产1-[2-(2,4-二甲基-苯基硫烷基)-苯基]-哌嗪的方法
CN104797566B (zh) 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
MX362886B (es) 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
EP2958903B1 (en) * 2013-02-22 2017-04-12 H. Lundbeck A/S Vortioxetine manufacturing process
CN105283442B (zh) * 2013-04-04 2018-04-13 斯洛文尼亚莱柯制药股份有限公司 用于合成1‑(2‑((2,4‑二甲基苯基)硫代)苯基)哌嗪的方法
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
IN2013MU03121A (lt) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
JP6448645B2 (ja) 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) * 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016135636A1 (en) 2015-02-25 2016-09-01 Lupin Limited Process for the preparation of vortioxetine
US20180072690A1 (en) 2015-03-26 2018-03-15 Cipla Limited Methods for Making Serotonin Reuptake Inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CN108348486A (zh) * 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
US20180237386A1 (en) * 2015-08-19 2018-08-23 Amneal Pharmaceuticals Company Gmbh Process For Preparation Of Vortioxetine Hydrobromide
US20180303772A1 (en) * 2015-10-14 2018-10-25 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
TW201806599A (zh) 2016-07-01 2018-03-01 Ｈ 朗德貝克公司 用於快速開始抗抑鬱作用之給藥方案
BR112019000706A8 (pt) * 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
AU2017300463A1 (en) * 2016-07-22 2019-03-14 Jiangsu Nhwaluokang Pharmaceutical Research And Development Co., Ltd. Vortioxetine analogue and use and preparation thereof
WO2018042168A1 (en) 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
US11020390B2 (en) 2017-02-17 2021-06-01 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
US10836730B2 (en) 2017-02-23 2020-11-17 Unichem Laboratories Ltd. Process for preparation and purification of vortioxetine hydrobromide
BR112018076411A2 (pt) * 2017-04-25 2019-04-09 H. Lundbeck A/S processo para a preparação de hbr de vortioxetina na forma alfa
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
SI3810582T1 (sl) 2018-06-20 2024-05-31 Vio Ag Pharmaceuticals S.A. Enolončni pristop z organo-psevdokatalitično aktivacijo c-h za pripravo vortioksetina in intermediata vortioksetina
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151755B1 (lt) 1971-04-13 1973-11-19
CS151751B1 (lt) 1971-04-13 1973-11-19
CS151752B1 (lt) 1971-04-13 1973-11-19
CS151753B1 (lt) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
DE69634678T2 (de) 1995-01-23 2006-01-19 Daiichi Suntory Pharma Co., Ltd. Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69830045T2 (de) * 1997-10-31 2006-01-12 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinopropanol und Arylpiperazinopropanol Derivate und dieselbe ent- haltende Pharmazeutika
EE200100514A (et) 1999-04-02 2002-12-16 Icos Corporation LFA-1 ICAM-idega seondumise inhibiitorid ja nendekasutamine
CA2381008A1 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU766592B2 (en) * 1999-09-14 2003-10-16 Pharmacopeia, Inc. Article comprising a multi-channel dispensing head
EP1246819A1 (en) 1999-12-30 2002-10-09 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
KR100790916B1 (ko) * 1999-12-30 2008-01-03 하. 룬트벡 아크티에 셀스카브 치환 페닐-피페라진 유도체, 그들의 제조 및 사용
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
JP2004523530A (ja) * 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
IL161966A0 (en) * 2001-12-20 2005-11-20 Lundbeck & Co As H Aryloxyphenyl and arylsulfanylphenyl
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
AU2004226838B8 (en) * 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP2044043B2 (en) * 2006-06-16 2021-03-03 H. Lundbeck A/S 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment

Also Published As

Publication number Publication date
EP1436271A1 (en) 2004-07-14
ZA200401583B (en) 2005-05-25
NO20041628L (no) 2004-04-21
EA011096B1 (ru) 2008-12-30
US20180127389A1 (en) 2018-05-10
US9090575B2 (en) 2015-07-28
PT1749818E (pt) 2009-10-06
UA81749C2 (uk) 2008-02-11
CY1107924T1 (el) 2013-09-04
US8110567B2 (en) 2012-02-07
US20120302553A1 (en) 2012-11-29
AR036659A1 (es) 2004-09-22
DE60233608D1 (de) 2009-10-15
US20110009423A1 (en) 2011-01-13
NO332355B1 (no) 2012-09-03
AR066460A2 (es) 2009-08-19
PL209253B1 (pl) 2011-08-31
HRP20040220A2 (en) 2005-02-28
JP2007051149A (ja) 2007-03-01
MEP6508A (xx) 2010-02-10
JP3955613B2 (ja) 2007-08-08
EG25095A (en) 2011-08-17
ES2328725T3 (es) 2009-11-17
ES2298425T3 (es) 2008-05-16
IS2578B (is) 2010-02-15
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
US8476279B2 (en) 2013-07-02
LU92397I2 (fr) 2014-05-12
CA2462110C (en) 2010-05-11
CA2462110A1 (en) 2003-04-10
RS20120158A2 (en) 2012-10-31
ATE386730T1 (de) 2008-03-15
HUP0402313A3 (en) 2010-03-29
FR14C0033I2 (fr) 2014-11-14
IL160655A0 (en) 2004-07-25
EA007537B1 (ru) 2006-10-27
DE60225162D1 (de) 2008-04-03
BR0212733B1 (pt) 2014-05-13
EA200400498A1 (ru) 2004-08-26
NO2014011I1 (no) 2014-05-13
BR122012009534B1 (pt) 2018-02-27
US20160137620A1 (en) 2016-05-19
KR20070103515A (ko) 2007-10-23
AU2006215994A9 (en) 2006-10-05
DK1436271T3 (da) 2008-06-09
DE60225162T2 (de) 2009-02-12
ME00039B (me) 2010-06-10
NL300652I1 (lt) 2016-01-18
HUS1400012I1 (hu) 2020-12-28
BR122012023120B1 (pt) 2017-03-21
ATE441631T1 (de) 2009-09-15
BR122012023120B8 (pt) 2022-01-18
US20060084662A1 (en) 2006-04-20
DK1749818T3 (da) 2009-10-12
RS27704A (en) 2006-10-27
PT1436271E (pt) 2008-04-10
EA007537B3 (ru) 2015-02-27
AU2002333220B2 (en) 2008-02-07
KR20040047886A (ko) 2004-06-05
BRPI0212733B8 (pt) 2021-05-25
AU2006215994A1 (en) 2006-10-05
BE2014C036I2 (lt) 2021-11-22
JP3896116B2 (ja) 2007-03-22
AU2002333220A2 (en) 2003-04-14
CA2462110E (en) 2003-04-10
DE60225162T3 (de) 2022-08-11
BR122012009534C8 (pt) 2021-05-25
US20060089368A1 (en) 2006-04-27
JP2007031447A (ja) 2007-02-08
US10844029B2 (en) 2020-11-24
AU2006215994A2 (en) 2006-10-05
KR20060118020A (ko) 2006-11-17
CY2014022I1 (el) 2015-12-09
EP1436271B1 (en) 2008-02-20
IS2732B (is) 2011-04-15
NO326443B1 (no) 2008-12-08
US7148238B2 (en) 2006-12-12
IS7164A (is) 2004-02-26
WO2003029232A1 (en) 2003-04-10
FR14C0033I1 (lt) 2014-06-13
EP1436271B3 (en) 2022-04-20
NO20083446L (no) 2004-04-21
KR100770194B1 (ko) 2007-10-25
US7683053B2 (en) 2010-03-23
US7138407B2 (en) 2006-11-21
CO5580746A2 (es) 2005-11-30
JP3955614B2 (ja) 2007-08-08
EP1749818A3 (en) 2008-04-02
KR100842702B1 (ko) 2008-07-01
HU230189B1 (hu) 2015-09-28
IS8806A (is) 2009-03-10
MY140950A (en) 2010-02-12
CN1561336A (zh) 2005-01-05
DK1436271T6 (da) 2022-06-27
EA200601269A1 (ru) 2007-02-27
RS20120158A3 (en) 2013-10-31
JP2005505585A (ja) 2005-02-24
PL368442A1 (en) 2005-03-21
NO2014011I2 (no) 2015-08-31
US20210276966A1 (en) 2021-09-09
NL300652I2 (lt) 2016-01-18
MXPA04002959A (es) 2004-07-05
RS52865B (en) 2013-12-31
UA93857C2 (uk) 2011-03-25
US20070060574A1 (en) 2007-03-15
CY1110064T1 (el) 2015-01-14
AU2002333220C1 (en) 2023-10-05
US20140163043A1 (en) 2014-06-12
ES2298425T7 (es) 2022-06-27
US7144884B2 (en) 2006-12-05
SI1436271T1 (sl) 2008-06-30
CY2014022I2 (el) 2015-12-09
EP1749818B1 (en) 2009-09-02
BR0212733A (pt) 2004-11-16
LTC1436271I2 (lt) 2016-09-12
US9708280B2 (en) 2017-07-18
BR122012009534B8 (pt) 2019-01-29
PL210551B1 (pl) 2012-02-29
AU2006215994B2 (en) 2008-11-13
HUP0402313A2 (hu) 2005-02-28
CN1319958C (zh) 2007-06-06
US20050014740A1 (en) 2005-01-20
KR100783346B1 (ko) 2007-12-07
EP1749818A2 (en) 2007-02-07
HU228956B1 (en) 2013-07-29

Similar Documents

Publication Publication Date Title
HUS1400012I1 (hu) Szerotonin újrafelvételt gátló fenilpiperazin-származékok
PL364580A1 (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
AU2002306491A1 (en) Serotonin reuptake inhibitor formulations
IL149105A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors
PL364821A1 (en) Phenylpiperazines as serotonin reuptake inhibitors
AP2005003467A0 (en) N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors.
IL154343A0 (en) Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
IL158141A0 (en) Phenyl heterocyclyl ether derivatives as serotonin reuptake inhibitors
IL162308A0 (en) Aminoindane derivatives as serotonin and norepinephrine uptakeinhibitors
HK1095135A1 (en) Morpholine derivatives as norepinephrine reuptake inhibitors
AU2002366766A1 (en) Serotonine reuptake inhibitor
PL369525A1 (en) Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20221001